Business Ranitidine recall: Patient safety is our first priority, next step depends on test results, says GSK vice-president Updated : September 27, 2019 01:25 PM IST It is a Rs 200-crore focus brand in India; the company to find out a way to manage the financial impact of the recall. It’s premature to give the financial impact because we are expecting some test results, says GSK Pharma VP and South Asia MD A Vaidheesh. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.